This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand


Kulkantrakorn, Kongkiat, Tanyakitpisal, Panas, Towanabut, Somchai, Dejthevaporn, Charungthai, Rangseekajee, Poonsri, Pongpakdee, Sunsanee, Laptikultham, Somsak, Rodprasert, Kritsada, Setthawatcharawanich, Suwanna, Thinkhamrop, Bandit


Psychogeriatrics: The Official Journal Of The Japanese Psychogeriatric Society, Volume: 13, No.: 1, Pages.: 1-8

Year of Publication



Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, hospital-based, prospective observational study was conducted in nine hospitals across Thailand. Patients with probable mild to moderate AD who received the rivastigmine patch were enrolled. Data were collected data at baseline, weeks 4-8 and after week16.; Results: A total of 116 AD patients were screened, and three were excluded. Of 113 patients, 62.8% were women with a mean age of 73.3 ± 9.2 years; 79.7% were newly diagnosed. One-third of all patients had been using antipsychotic or antidepressant medication. Common comorbidities were hypertension and dyslipidemia. The Thai Mental State Examination score significantly increased from 18.6 to 20.3 (weeks 4-8) and 20.4 (week 16+) (P < 0.001). Scores based on physicians' (Clinical Global Impression) and caregivers' (Patients' Caregiver Global Impression of Change) impressions of improvement suggested minimal improvement. Because of adverse events, seven patients's dosages were reduced 10 cm(2) to 5 cm(2) or from 5 cm(2) to nothing. Itching was the most common adverse symptom.; Conclusions: During the first 16 weeks after initiation of rivastigmine patch therapy, patients with probable mild to moderate AD had statistically significant improvement in cognitive function, but clinically marginal benefit. Rivastigmine was safe and well tolerated.; © 2012 The Authors. Psychogeriatrics © 2012 Japanese Psychogeriatric Society.

Bibtex Citation

@article{KULKANTRAKORN_2012, doi = {10.1111/j.1479-8301.2012.00403.x}, url = {}, year = 2012, month = {feb}, publisher = {Wiley-Blackwell}, volume = {13}, number = {1}, pages = {1--8}, author = {Kongkiat KULKANTRAKORN and Panas TANYAKITPISAL and Somchai TOWANABUT and Charungthai DEJTHEVAPORN and Poonsri RANGSEEKAJEE and Sunsanee PONGPAKDEE and Somsak LAPTIKULTHAM and Kritsada RODPRASERT and Suwanna SETTHAWATCHARAWANICH and Bandit THINKHAMROP}, title = {Rivastigmine patch for treatment of Alzheimer{textquotesingle}s disease in clinical practice in Thailand}, journal = {Psychogeriatrics} }


37, administration & dosage, adverse effects, aged, alzheimer disease, cholinesterase inhibitors, cognition, drug effects, drug therapy, female, humans, male, middle aged, phenylcarbamates, prospective studies, psychology, rivastigimine, severity of illness index, thailand, transdermal patch, treatment outcome

Countries of Study


Types of Study

Before and After Study

Type of Outcomes



Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime